A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design
Phase: PHASE2 | Sponsor: TRYP Therapeutics | Compound: Psilocybin
- Status
- active
- Institution
- TRYP Therapeutics
- Start date
- 2024-01-17
- End date
- 2026-03-01
- Registry ID
- NCT06206265
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.